Genelux Corporation Common Stock (GNLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has a cash flow conversion efficiency ratio of -0.354x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.58 Million) by net assets ($18.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genelux Corporation Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Genelux Corporation Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GNLX total liabilities for a breakdown of total debt and financial obligations.
Genelux Corporation Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genelux Corporation Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chinyang Hold
KO:100250
|
-0.015x |
|
Cantor Equity Partners, Inc. Class A Ordinary Shares
NASDAQ:CEP
|
N/A |
|
Kc Cottrell
KO:119650
|
-0.341x |
|
Arcticzymes Technologies ASA
OL:AZT
|
0.026x |
|
Buda Juice, Inc.
NYSE MKT:BUDA
|
0.324x |
|
DAM CAPITAL ADVISORS LTD
NSE:DAMCAPITAL
|
N/A |
|
United Utilities Group PLC
LSE:UU
|
0.345x |
|
Thai Steel Cable Public Company Limited
BK:TSC
|
0.023x |
Annual Cash Flow Conversion Efficiency for Genelux Corporation Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Genelux Corporation Common Stock from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Genelux Corporation Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $26.27 Million | $-21.23 Million | -0.808x | +22.40% |
| 2023-12-31 | $19.47 Million | $-20.27 Million | -1.041x | -1143.31% |
| 2022-12-31 | $-35.78 Million | $-3.57 Million | 0.100x | -49.82% |
| 2021-12-31 | $-33.11 Million | $-6.58 Million | 0.199x | -37.47% |
| 2020-12-31 | $-22.66 Million | $-7.21 Million | 0.318x | +9.24% |
| 2019-12-31 | $-24.81 Million | $-7.22 Million | 0.291x | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or s… Read more